Inflammation-related genes and the risk of Parkinson’s disease: a multilocus approach
J. Infante
Service of Neurology and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), University Hospital ‘Marqués de Valdecilla’ (University of Cantabria), Santander, Spain
Search for more papers by this authorI. García-Gorostiaga
Service of Neurology and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), University Hospital ‘Marqués de Valdecilla’ (University of Cantabria), Santander, Spain
Search for more papers by this authorP. Sánchez-Juan
Institute for Formation and Research of the Foundation ‘Marqués de Valdecilla’ (IFIMAV), Santander, Spain
Search for more papers by this authorC. Sánchez-Quintana
Service of Neurology and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), University Hospital ‘Marqués de Valdecilla’ (University of Cantabria), Santander, Spain
Search for more papers by this authorJ. L. Gurpegui
Service of Neurology, Laredo Hospital, Laredo, Spain
Search for more papers by this authorE. Rodríguez-Rodríguez
Service of Neurology and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), University Hospital ‘Marqués de Valdecilla’ (University of Cantabria), Santander, Spain
Search for more papers by this authorI. Mateo
Service of Neurology and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), University Hospital ‘Marqués de Valdecilla’ (University of Cantabria), Santander, Spain
Search for more papers by this authorJ. Berciano
Service of Neurology and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), University Hospital ‘Marqués de Valdecilla’ (University of Cantabria), Santander, Spain
Search for more papers by this authorO. Combarros
Service of Neurology and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), University Hospital ‘Marqués de Valdecilla’ (University of Cantabria), Santander, Spain
Search for more papers by this authorJ. Infante
Service of Neurology and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), University Hospital ‘Marqués de Valdecilla’ (University of Cantabria), Santander, Spain
Search for more papers by this authorI. García-Gorostiaga
Service of Neurology and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), University Hospital ‘Marqués de Valdecilla’ (University of Cantabria), Santander, Spain
Search for more papers by this authorP. Sánchez-Juan
Institute for Formation and Research of the Foundation ‘Marqués de Valdecilla’ (IFIMAV), Santander, Spain
Search for more papers by this authorC. Sánchez-Quintana
Service of Neurology and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), University Hospital ‘Marqués de Valdecilla’ (University of Cantabria), Santander, Spain
Search for more papers by this authorJ. L. Gurpegui
Service of Neurology, Laredo Hospital, Laredo, Spain
Search for more papers by this authorE. Rodríguez-Rodríguez
Service of Neurology and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), University Hospital ‘Marqués de Valdecilla’ (University of Cantabria), Santander, Spain
Search for more papers by this authorI. Mateo
Service of Neurology and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), University Hospital ‘Marqués de Valdecilla’ (University of Cantabria), Santander, Spain
Search for more papers by this authorJ. Berciano
Service of Neurology and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), University Hospital ‘Marqués de Valdecilla’ (University of Cantabria), Santander, Spain
Search for more papers by this authorO. Combarros
Service of Neurology and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), University Hospital ‘Marqués de Valdecilla’ (University of Cantabria), Santander, Spain
Search for more papers by this authorAbstract
For the first time, the multilocus approach by the set-association method has been applied for the analysis of a cluster of five genes [tumor necrosis factor α (TNF-α), interleukin 6 (IL-6), IL-8, IL-1α and IL-10] involved in the brain neuroinflammatory pathway in Parkinson’s disease (PD), in a well-defined group of 197 PD patients and 173 control subjects from Spain. Set-association analysis did not reveal an independent or an interactive effect of these inflammatory genes on the PD risk.
References
- 1 Bartels AL, Leenders KL Neuroinflammation in the pathophysiology of Parkinson’s disease: evidence from animal models to human in vivo studies with [(11)C]-PK11195 PET. Movement Disorders 2007; 22: 1852–1856.
- 2 Hunot S, Hirsch EC. Neuroinflammatory processes in Parkinson’s disease. Annals of Neurology 2003; 53(Suppl. 3): S49–S58; discussion S58–S60.
- 3 Daniel SE, Lees AJ. Parkinson’s Disease Society Brain Bank, London: overview and research. Journal of Neural Transmission. Supplementum 1993; 39: 165–172.
- 4 Hoh J, Wille A, Ott J. Trimming, weighting, and grouping SNPs in human case-control association studies. Genome Research 2001; 11: 2115–2119.
- 5 Nishimura M, Mizuta I, Mizuta E, et al. Tumor necrosis factor gene polymorphisms in patients with sporadic Parkinson’s disease. Neuroscience Letters 2001; 311: 1–4.
- 6 Wu YR, Feng IH, Lyu RK, et al. Tumor necrosis factor-alpha promoter polymorphism is associated with the risk of Parkinson’s disease. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 2007; 144: 300–304.
- 7 Hakansson A, Westberg L, Nilsson S, et al. Interaction of polymorphisms in the genes encoding interleukin-6 and estrogen receptor beta on the susceptibility to Parkinson’s disease. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 2005; 133: 10, 88–92.
- 8 Ross OA, O’Neill C, Rea IM, et al. Functional promoter region polymorphism of the proinflammatory chemokine IL-8 gene associates with Parkinson’s disease in the Irish. Human Immunology 2004; 65: 340–346.
- 9 Infante J, Sanz C, Fernandez-Luna JL, Llorca J, Berciano J, Combarros O. Gene–gene interaction between interleukin-1A and interleukin-8 increases Alzheimer’s disease risk. Journal of Neurology 2004; 251: 482–483.
- 10 Hayes A, Green EK, Pritchard A, et al. A polymorphic variation in the interleukin 1A gene increases brain microglial cell activity in Alzheimer’s disease. Journal of Neurology, Neurosurgery, and Psychiatry 2004; 75: 1475–1477.
- 11 Wu YR, Chen CM, Hwang JC, et al. Interleukin-1alpha polymorphism has influence on late-onset sporadic Parkinson’s disease in Taiwan. Journal of Neural Transmission 2007; 114: 1173–1177.
- 12 Schulte T, Schols L, Muller T, Woitalla D, Berger K, Kruger R. Polymorphisms in the interleukin-1 alpha and beta genes and the risk for Parkinson’s disease. Neuroscience Letters 2002; 326: 70–72.
- 13 Moller JC, Depboylu C, Kolsch H, et al. Lack of association between the interleukin-1 alpha (-889) polymorphism and early-onset Parkinson’s disease. Neuroscience Letters 2004; 359: 195–197.
- 14 Arimoto T, Choi DY, Lu X, et al. Interleukin-10 protects against inflammation-mediated degeneration of dopaminergic neurons in substantia nigra. Neurobiology of Aging 2006; (Epub ahead of print).
- 15 Hakansson A, Westberg L, Nilsson S, et al. Investigation of genes coding for inflammatory components in Parkinson’s disease. Movement Disorders 2005; 20: 569–573.
- 16 Infante J, Sanz C, Fernandez-Luna JL, Llorca J, Berciano J, Combarros O. Gene–gene interaction between interleukin-6 and interleukin-10 reduces AD risk. Neurology 2004; 63: 1135–1136.
- 17 Papassotiropoulos A, Wollmer MA, Tsolaki M, et al. A cluster of cholesterol-related genes confers susceptibility for Alzheimer’s disease. The Journal of Clinical Psychiatry 2005; 66: 940–947.
